Patients with beneficial inflammatory-marker changes had higher baseline proportions of Faecalibacterium, Leuconostoc , and Odoribacter  compared to corresponding non-responders. CONCLUSIONS & INFERENCES: Identifying patients with a more amenable microbiome at treatment initiation may result in better treatment response.